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Introduction: Biglycan is an important proteoglycan of the extracellular matrix of intervertebral disc (IVD), and its
decrease with aging has been correlated with IVD degeneration. Biglycan deficient (Bgn−/0) mice lack this protein
and undergo spontaneous IVD degeneration with aging, thus representing a valuable in vivo model for preliminary
studies on therapies for human progressive IVD degeneration. The purpose of the present study was to assess the
possible beneficial effects of adipose-derived stromal cells (ADSCs) implants in the Bgn−/0 mouse model.
Methods: To evaluate ADSC implant efficacy, Bgn−/0 mice were intradiscally (L1-L2) injected with 8x104 ADSCs at
16 months old, when mice exhibit severe and complete IVD degeneration, evident on both 7Tesla Magnetic
Resonance Imaging (7TMRI) and histology. Placebo and ADSCs treated Bgn−/0 mice were assessed by 7TMRI analysis
up to 12 weeks post-transplantation. Mice were then sacrificed and implanted discs were analyzed by histology
and immunohistochemistry for the presence of human cells and for the expression of biglycan and aggrecan in the
IVD area.
Results: After in vivo treatment, 7TMRI revealed evident increase in signal intensity within the discs of mice that
received ADSCs, while placebo treatment did not show any variation. Ultrastructural analyses demonstrated that
human ADSC survival occurred in the injected discs up to 12 weeks after implant. These cells acquired a positive
expression for biglycan, and this proteoglycan was specifically localized in human cells. Moreover, ADSC treatment
resulted in a significant increase of aggrecan tissue levels.
Conclusion: Overall, this work demonstrates that ADSC implant into degenerated disc of Bgn−/0 mice ameliorates
disc damage, promotes new expression of biglycan and increased levels of aggrecan. This suggests a potential
benefit of ADSC implant in the treatment of chronic degenerative disc disease and prompts further studies in
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The degeneration of the intervertebral disc (IVD) is a
physio-pathological process accelerating with age and
considered as the major cause of diverse spine disorders.
Indeed, IVD degeneration represents the main cause of
the low-back pain that affects the majority of the adult
population, and causes a huge loss of time from work as
well as relevant medical expenses [1]. As demonstrated
by Furukawa et al. [2], the degenerative changes in the
IVD that occur in pathologic processes are similar to
those associated with normal aging. In addition, IVD de-
generation may be premature or early onset of the aging
process, or taken as a distinct process from aging [3].
The IVD is the largest enclosed and avascular tissue of
the human body, and possesses a peculiar microenviron-
ment, characterized by high mechanical and osmotic
pressures, severe hypoxia, and a very limited supply of
nutrients [4]. Its core, called the nucleus pulposus (NP),
is composed of a jelly-like material that consists mainly
of water, as well as the extracellular matrix (ECM) com-
ponents, including a loose network of collagen fibers
and proteoglycans. This ECM composition is similar to
the articular cartilage, as it contains several members of
the small leucine repeat proteoglycans (SLRPs) family
[5]. Temporal and spatial expressions of some SLRPs, in
particular biglycan, have been demonstrated in the hu-
man IVD [6-8] and their decreasing level appears to cor-
relate with age and degeneration of human IVD [9]. IVD
degeneration has been found to spontaneously occur in
biglycan-deficient (Bgn−/0) mice, which therefore repre-
sent a valuable in vivo model to study degenerative disc
disease [2]. In this animal model, 7-Tesla magnetic reson-
ance imaging (7TMRI) is a noninvasive tool that is able to
evaluate pathological evolution over time and therapeutic
follow up [10].
Different therapies have been proposed for the treatment
of IVD degeneration, and among them, the use of cell ther-
apy strategies to supplement/replenish the cell population
in IVD degeneration appears promising [11-13]. For ex-
ample, rabbit annulus fibrosus (AF) cells cultured in an
atelocollagen honeycomb-shaped scaffold have been allo-
grafted into the lacunae of NP of rabbit IVD to treat
degeneration through a tissue-engineering method. This
approach showed in vivo cell proliferation activity with a
hyaline-like cartilage production [14].
Our group has recently demonstrated that it is possible
to isolate mesenchymal stromal cells from pathological
IVD samples, and these cells exhibit stem-cell-like proper-
ties [15]. Despite the fact that mesenchymal stromal cells
represent a good in vitro tool to clarify the mechanisms
underlying IVD degeneration, their use in cell therapy for
spinal disorders remains unknown, mainly due to diffi-
culty obtaining normal IVD tissue specimens as well as a
sufficient number of cells required for therapy. Besidesstromal cells derived from IVD tissue, it has been sug-
gested that mesenchymal stromal cells derived from the
adipose tissue (ADSCs) could be more accessible and ef-
fective cells to treat IVD disease [16,17]. Indeed, ADSCs
can be easily isolated from fat tissue of patients with IVD
degeneration, and of relevance, they exhibit both prolifera-
tive and differentiation capability in appropriate culture
conditions [18].
In the present study we assess the possibility to improve
disc regeneration by intradiscal injection of ADSCs in the
spontaneous and progressive model of IVD degeneration
of Bgn−/0 mice, where IVD changes and degeneration
occur due to byglican deficiency [2]. We focused on the
efficacy of the cell therapy monitoring treatment effects by
high resolution in vivo imaging and ex vivo histological
examination of IVD tissues. We additionally investigated
whether ADSC implant increases the production of bigly-
can and aggrecan in the degenerated IVD.
Methods
ADSC isolation and expansion
The study was approved by the local institutional review
board of the IRCCS Foundation Neurological Institute
“C. Besta” (Milan, Italy), and conformed to the WMA
Declaration of Helsinki. Patients’ informed consent to the
procedure was obtained. Adipose tissue was collected
from peri-umbilical adipose tissue from four healthy male
donors (mean age, 45 ± 6 years) undergoing elective ab-
dominal surgery. In particular, abdominal subcutaneous
fat specimens of about 1 to 2 cm3 (corresponding to 1 to
2 g) were obtained by needle aspiration from the peri-
umbilical area, under local anesthesia (1% xylocaine).
Once the tissue was aspirated, the sample was placed in
a Falcon tube containing Dulbecco’s phosphate-buffered
saline (D-PBS) (Euroclone, Milan, Italy) (1:1, w/v) with
the addition of penicillin and streptomycin solution
(1%) (Sigma-Aldrich, Basel, Switzerland), and sent to
the laboratory for tissue processing.
The adipose tissue was extensively washed with D-PBS
and after centrifugation (300 g, 12 minutes), the infrana-
tant, containing hematopoietic cells, was removed. The tis-
sue was cut into small pieces with fine scissors (Martin
KLS, Tuttlingen, Germany), and then mechanically dissoci-
ated using a 1-mL aerosol-resistant tip. Cells were resus-
pended in 10 mL D-PBS and centrifuged at 123 g for
10 minutes. The pellet was resuspended in 500 μL of
D-PBS and again mechanically dissociated by a 200-μL
aerosol-resistant tip. Cells were resuspended again and cen-
trifuged as described above. Finally, the pellet was resus-
pended in 10 mL of chemically defined Stem Cells Medium
(SCM) [15,19]. The SCM composition consisted of
DMEM-F-12 supplemented with 10% FBS (Gibco, Grand
Island, NY, USA), 10 ng/mL basic fibroblast growth factor
2 (FGF2) (human recombinant, Peprotech, Rocky Hill, NJ,
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and 20 ng/mL epidermal growth factor (EGF) (human re-
combinant, Sigma-Aldrich, Milan, Italy). Cells were then
seeded in tissue culture plates (NUNC, Thermo Scientific
Illkirch, Cedex, France) at 1 to 3.5 × 103/cm2 density and
were maintained in a humidified incubator with 5% CO2
at 37°C. After 24 to 48 h from plating, cultures were gently
washed with D-PBS to remove unattached cells and then
fed with fresh media. When cells achieved about 70% con-
fluence, they were detached from the tissue culture plates
using TrypLE Select (Gibco) and plated at a density of 5 ×
103 cells/cm2. Cultures between passage 3 (P3) and pas-
sage 5 (P5) were expanded and used for experimental ana-
lyses. The remaining cells were cryopreserved in
cryopreservation medium composed of dimethylsulfoxide
(Sigma Aldrich) (10% in FBS).
Flow cytometric immunophenotyping
For each sample, 5 × 104 ADSCs between P3 and P5 were
characterized by means of fluorescence-activated cell sorting
(FACS). Cells were incubated with appropriate phycoerytrin
(PE)- or fluorescein isothiocyanate (FITC)- conjugated
monoclonal antibodies to test the expression of a pat-
tern of mesenchymal, hematopoietic, endothelial and
immunological markers including: CD14, CD34, CD45,
CD73, HLA-DR (BD Pharmingen, San Jose, CA, USA),
CD105 (AbDSerotec, Raleigh, NC, USA), CD90 (Millipore
Temecula, CA, USA) and CD19 (Beckman Coulter, Cas-
sina de’ Pecchi, Milano, Italy). After 30 minutes at 4°C,
cells were washed once with D-PBS, fixed with 4% parafor-
maldehyde (PFA) (Sigma Aldrich), and analyzed using a
FACS scan flow cytometer and Cell Quest software (BD
Pharmingen, San Jose, CA, USA). According to the manu-
facturers’ instructions, specific isotype-matched mouse im-
munoglobulins (BD Pharmingen) were used as control. At
least 2 × 104 events were acquired for each sample. Non-
viable cells or cell debris were excluded by physical gating.
Multipotent differentiation capacity of ADSCs
ADSCs were tested for their capacity to differentiate into
adipocytes, chondrocytes and osteocytes according to
the minimal criteria suggested by Dominici et al. [20].
The procedure was described by Navone et al. [21]
(Materials and methods).
Experimental animals
Procedures involving animals and their care were con-
ducted in conformity with all procedures following insti-
tutional guidelines which, in turn, are in compliance
with national (DL number 116, GU Suppl. 40, February
18 1992, Circolare number 8, GU, 14 July 1994) and
international laws and policies (EEC Council Directive
86/609, OJ L 358, 1 December 2012, 1987; NIH Guide
for the Care and Use of Laboratory Animals, US NationalResearch Council, 1996). The protocol for the use of la-
boratory animals was approved by the ethical committee
of the IRCCS Foundation Neurological Institute “C. Besta”
(Milan, Italy), and by the Italian Ministry of Health (num-
ber NTN-01-10). Bgn−/0 mice, generated by gene targeting
in embryonic stem cells [22], were kindly provided by Dr
Marian Young (National Institutes of Health, Bethesda,
MD, USA), Dr Ariane Melchior-Becker and Dr Jens W
Fischer (University of Essen, Germany) and Dr Liliana
Schaefer (Johann Wolfgang Goethe-University, Frankfurt,
Germany). C57Bl6 mice were purchased from Charles
River (Calco, Lecco, Italy). We used male mice for experi-
mental animals because the biglycan gene is located on
the X chromosome and absent from the Y chromosome.
All mice maintained their hybrid (C57Bl6/129) genetic
background. DNA was isolated from tail samples, and the
genotype of the wild type (WT) and Bgn−/0 mice was de-
termined by PCR [23]. The successful genetic deletion in
Bgn−/0 mice was previously assessed by the absence of
biglycan mRNA and protein [22]. Animals were enrolled
at 6 months of age and characterized for disc degeneration
until 19 months by 7TMRI (7 T Biospec 70/30 USR, Bru-
ker, Ettlingen, Germany). C57Bl6 (n =10) male mice were
considered as WT controls. All animals were supplied
with food and water ad libidum. Temperature, humidity
and night-day cycles were maintained according to the
standards set up by the research animal services.
MRI characterization of the animal model
In order to study the timing of disc degeneration and
evaluate the time of cell implantation, Bgn−/0 mice (n =10)
and WT mice (n =10) were monitored every 2 weeks from
6 months to 18 months of age with the same acquisition
protocol.
Preparation of ADSCs for transplant
ADSCs isolated from the four donors satisfied criteria
proposed by Dominici et al. [20]. Briefly, ADSCs, which
are plastic-adherent when maintained in standard cul-
ture conditions, expressed CD105, CD73 and CD90, and
lacked expression of CD45, CD34, CD14, CD19 and
HLA-DR surface molecules. When cultured in a select-
ive culture condition, ADSCs were able to differentiate
into osteoblasts, adipocytes and chondroblasts. After four
in vitro passages, ADSCs derived from one donor were
harvested by Tryple Select (Gibco), washed and resus-
pended in saline solution.
Procedure of ADSC injection into the IVD in Bgn−/0 mice
At 16 months of age, after confirmation of disc degener-
ation by 7TMRI, ADSCs or saline were administrated ac-
cording to the following procedure. General anesthesia,
consisting of induction with 5% isoflurane (Aerrane, One
Baxter Parkway, Deerfield IL, USA) in 30% oxygen in air
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maintained with 2.0 ± 0.4% isoflurane. Five minutes after
induction of anesthesia, supplemental analgesia was
provided by intraperitoneal injection of buprenorphine
(Sigma Aldrich) (0.3 mg/kg in saline, 1 mL given over
5 minutes). With the animals (n =10 each for placebo
and the ADSC-transplanted group) lying supine, both
the abdominal skin and peritoneum were incised. The
bowel was displaced to allow an anterior approach to
the lumbar vertebral segment. IVD at the level of the
first lumbar vertebra (L1) to L2 was exposed and ADSCs
or saline treatment was administrated by a Hamilton syr-
inge (using a 33-gauge blunt needle). Cells (8 × 104) or sa-
line were injected 1 mm deep in a final volume of 5 μL in a
time of 2 minutes. After injection, the needle was main-
tained inside the disc for a further 2 minutes to reduce the
spilling of the injection solution. The bowel was then
repositioned and the wound was closed using 5–0
Nylon suture (Ethicon Inc., Somerville, NJ, USA). Post-
intervention animals were left to recover on heated pads
and then transferred to their own cages, and monitored
daily for 3 months.
Radiological evaluation
The effectiveness of ADSC transplantation on L1 to L2
discs was evaluated by 7TMRI of the lumbar tract of the
spine one day before transplantation, immediately after
surgery (30 minutes) and every 14 days until 12 weeks
after transplantation. The acquisition protocol was opti-
mized in order to reduce exposure time to anesthesia.
Acquisition protocol
The experiments were carried out using a high-field
7TMRI (Bruker) scanner equipped with a gradient system
reaching the maximum amplitude of 400 mT/m. Mice
were anesthetized with 1.5 to 2.0% isoflurane (flow rate
0.8 L/minute) and positioned on an animal bed equipped
with a nosecone for gas anesthesia. To detect the depth of
anesthesia and the animal health condition during the
MRI study, the respiratory rate and temperature were
monitored by a pneumatic and rectal sensor, respectively.
A 75-mm birdcage linear coil (Rapid Mr International,
Columbus, OH, USA) was used for radio frequency ex-
citation and a rat brain surface coil (Rapid) was used for
signal reception. Animals were placed supine on the rat
brain surface coil, so that the lumbar tract of the spine
could be placed at the centre of the coil’s sensitive part.
For anatomical references and to test the correct animal
alignment in the magnet bore, T2-weighted images (T2-
wi) were acquired in three orthogonal planes: axial,
sagittal, and coronal. The acquisition protocol included
T1- and high-resolution T2-wi. T1-wi was acquired by
spin echo sequence with echo time (TE) 11.720 ms, repe-
tition time (TR) 401.306 ms, slice thickness (ST) 1 mm,in-plane resolution 0.105 mm, number of averages (NA) 6
and high resolution T2-wi by a rapid acquisition with re-
laxation enhancement (RARE) sequence (TR/TE =3000/
14 ms, RARE factor =8, slice thickness =0.07 mm, in plane
resolution =0.086 mm, NA =8). Both sequences investi-
gated the three orthogonal orientations: axial, coronal
and sagittal.
MRI assessment of IVD regeneration after ADSC
transplantation
Once the acquisition protocol had been optimized and
implantation time determined, the whole protocol was
repeated on mice in the placebo group (n =10) and in
the ADSCs group (n =10), every two weeks for three
months after implantation; the mouse being placed in
the same position for easier inter-scan comparison.
Post processing
A signal intensity index was determined to assess the de-
gree of disc regeneration after transplantation. The oper-
ated discs were identified on the high resolution T2-wi
and the signal intensity was quantified on the correspond-
ing axial T1- and T2-wi slice using Paravision software
(Paravision 5.1, Bruker). A circular region of interest of
1 mm2 was drawn at the center of the disc and in the adja-
cent spinal cord at every time point. The signal intensity
from the spinal cord was used as the intensity reference
within the scan and the index was therefore defined by
the ratio between the disc and the spinal cord signals; thus
the normalized indexes could be compared between dif-
ferent animals at different times [10]. Mean values were
computed in the L1 to L2 disc where histological examin-
ation detected the presence of implanted cells. The selec-
tion of regions of interest was repeated independently by
two blinded reviewers and the mean from the two values
was considered.
Histological confirmation
Animals were sacrificed at 12 weeks after ADSC in-
jection. The L1 to L4 vertebral bodies were entirely
fixed in 4% PFA containing 0.1 M sodium phosphate
buffer (Euroclone). After 3 weeks of decalcification with
RapidCal Immuno (BBC Biochemical, Mount Vernon,
WA, USA), the tissues were embedded in Optimal Cutting
Temperature (OCT) compound (Sakura Finetek, Torrance,
CA, USA) and sectioned to 20 μm thickness. The sec-
tions were stained with Safranin-O (Sigma Aldrich) and
counterstained with human specific anti-HuNu anti-
body (MAB 1281, Chemicon Millipore, Billerica, MA,
USA) (1:100) to identify human cells. The histological
grading system for disc degeneration devised by Masuda
[24] was used, focusing on the morphological changes in
the IVD structure. Each sample was interpreted by two
blinded histologists. The histological evidence of disc
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tissue matrix and IVD structure [25].
Immunohistochemistry
The disc sections were incubated overnight at 4°C with the
appropriate primary antibody against Human Nuclei
(HuNu), biglycan, aggrecan, Ki67 and Iba1, diluted in 1%
bovine serum albumin (BSA) in D-PBS. Sections were then
washed in D-PBS containing 0.1% BSA and incubated 1 h at
room temperature (RT) with a secondary antibody conju-
gated with a fluorochrome (Molecular Probes). Sections
were then washed and mounted in Vectashield H-1000
(Vector Laboratories, Peterborough, UK). The following pri-
mary antibodies were used: mouse anti-HuNu (1:100 dilu-
tion; Chemicon,), goat anti-human biglycan (1:250; Abcam,
Cambridge, UK), goat anti-human aggrecan (10 μg/mL;
R&D Systems, Minneapolis, MN, USA), rabbit anti-human
Ki67 (1:200; Chemicon), rabbit anti-mouse Iba1 (1 μg/mL;
Wako Chemicals GmbH, Neuss, Germany). Nuclear stain-
ing (1:5000; 4',6-diamidino-2-phenylindole (DAPI), (Invitro-
gen, Life Technology, Monza, Italy) was applied and used to
quantify the total number of cells. Immunohistochemistry
acquisitions were performed by two blinded observers.
Cell count
Images of cells positive to HuNu (as a marker of injected
ADSCs), and to biglycan and aggrecan (as markers of
in vivo differentiation) were acquired by microscopy (Leica
TCS SP2 AOBS, Leica Microsystems, Milan, Italy) after
specific immunocytochemical staining at 3 months after
transplantation. The quantification of positive cells was per-
formed by Axion Vision Software (Carl Zeiss Microscopy
GmbH, München Germany). Briefly, cell counts were per-
formed on a minimum of nine independent fields of photo-
micrographs captured with 40X objective. Total counts of
each marker’s immunoreactive cells were performed, and
the number of positive cells per culture was expressed as
percentage of total cells and of HuNu-positive cells.
Statistical analysis
The intensity index variation over time was evaluated by
SPSS software (IBM). Repeated-measures analysis of
variance (ANOVA) was performed pairwise at 3, 5 and
12 weeks post surgery with respect to baseline and be-
tween the groups at the same week. P-values lower than
0.05 were considered statistically significant. For each cell-
treated animal, we estimated the correlation between in-
tensity index and number of ADSCs found in the disc at
the histological exam.
Results
ADSC culture and phenotypic characterization
ADSCs were isolated from human adipose tissue sam-
ple obtained from healthy donors. After seeding inthe used culture conditions, isolated ADSCs grew as
adherent monolayer and presented a fusiform, fibroblastic-
like morphology.
Immunophenotypic FACS analysis of multiple surface
epitopes showed that ≥90% ADSCs expressed mesenchy-
mal stem cell (MSC) markers, including CD73, CD90, and
CD105 (Figure 1A). In contrast, less than 2% of ADSCs
expressed the hematopoietic cell markers CD14, CD34,
and CD45, and the immunological markers CD19 and
HLA-DR. Moreover, when cultured in selective media,
ADSCs exhibited tripotent differentiation capacity, being
able to differentiate into adipogenic, chondrogenic and
osteogenic cells (Figure 1B,C,D).
Identification of degeneration and regeneration from
7TMRI findings
Figure 2 shows sagittal T2-wi in an IVD Bgn
−/0 mouse
over time at 6, 11, 16 and 18 months of life (Figure 2A,
B,C,D, respectively). These MRI analyses of the Bgn−/0
mice revealed disc degeneration as a hypointense signal,
opposite to the usual bright signal in T2-wi of the WT
disc. The degeneration process was already observed at
11 months and reached maximal degeneration at 16 to
18 months, resulting in a complete hypointense signal,
which has been shown to be related to the loss of IVD
proteoglycans and water content [26]. Based on these re-
sults, using a ventral retroperitoneal approach at the level
of L1 to L2, Bgn−/0 mice were implanted with ADSCs at
16 months, when IVD degeneration was maximal. Of note,
the signal of IVDs in the WT mice strain (C57Bl6) at this
age did not show any intervertebral alteration (Figure 2E).
Figure 3 shows sagittal T2-wi of a placebo and an
ADSC-treated mouse pre-surgery, immediately post sur-
gery (30 minutes) and 5 and 12 weeks post surgery. MRI
revealed a visible increase in signal intensity within the
discs of mice implanted with ADSCs (Figure 3C,D). On
the contrary, placebo animals maintained low signal in-
tensity along with time (Figure 3A,B). Indeed, in the pla-
cebo group, we observed that the MRI indexes were
similar with time. In particular, this index was found to
be 0.60 ± 0.067 and 0.57 ± 0.045 at time 0 (pre-surgery)
and 12 weeks after injection, respectively, consistent with
animal enrollment at 16 months, when degeneration was
maximal. In contrast, in ADSC-treated mice the MRI
index distribution was increased at 3, 5 and 12 weeks with
respect to the baseline (pre-surgery) distribution, with
statistical significance at 3 and 5 weeks (Figure 4A). In
addition and of relevance, statistical analyses revealed a
significant increase in the MRI index of the transplanted
versus placebo mice at all investigated times, including
12 weeks (Figure 4A).
Twelve weeks after treatment, the slices of ADSC-
implanted discs were immunopositive for both Safranin-O
Figure 1 Features and immunophenotypic mesenchymal profile of human-derived adipose mesenchymal stem cell (ADSCs).
(A) Immunophenotypic mesenchymal profile of ADSCs shows that these cells express a high percentage of positivity for CD73, CD90, CD105, and
a low-positivity fraction for CD14, CD19, CD34, CD45 and HLA-DR. After selective stimulation, ADSCs exhibited adipogenic, chondrogenic and
osteogenic potential, which was demonstrated by Oil Red O staining of lipid droplets (B), aggrecan deposition (C), and Alizarin Red stained
calcium nodules (D).
Figure 2 Magnetic resonance imaging characterization of the intervertebral disc (IVD) of biglycan-deficient (Bgn−/0) and wild type (WT)
mice over time. T2-weighted images of the Bgn
−/0 mouse IVD were acquired at months (A) 6, (B) 11, (C) 16 and (D) 18, and of WT mice IVD at
month 16 of life (E). Boxes and arrows identify the spinal column level at vertebrae L1 to L2.
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Figure 3 Acquisitions of 7 Tesla magnetic resonance imaging on placebo and adipose mesenchymal stem cell (ADSC)-treated mice.
Sagittal T2-weighted (A,C) and axial T1-weighted images (B,D) of the lumbar tract are shown prior to (pre-surgery), 30 minutes after surgery
(post-surgery), and 5 and 12 weeks after treatment for a representative mouse treated with placebo (A,B) or ADSC implant (C,D) of the
degenerated disc. Violet boxes and arrows identify the spinal column level at vertebrae L1 to L2.
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respectively (Figure 4B).
The human cell number observed in the middle of the
section of the cell-transplanted disc exhibited an appre-
ciable correlation with the intensity index obtained by
MRI examination of the corresponding mouse (Figure 4C).
The correlation analysis was conducted in a group of eight
implanted discs and the mean value of the placebo groupFigure 4 Magnetic resonance imaging (MRI) index and adipose mese
index in transplanted mice at 0 (pre-surgery), 3, 5 and 12 weeks after ADSC
ADSC-implanted versus pre-surgery. The dotted line refers to placebo anim
injection. ♦P <0.05, ADSC-implanted versus placebo. (B) Representative inte
counterstaining with Safranin-O at 12 weeks after transplant. Scale bar, 100
at 12 weeks after transplant. Cell number was counted in a circular region
corresponding to zero ADSCs, represents the mean of placebo MRI values.was shown. The linear regression coefficient was R =0.73,
with a positive slope.
Histological analyses of IVD treated with ADSCs
At 12 weeks post-transplant, all mice were sacrificed and
IVD histology was performed. In the placebo group, all
animals revealed a disordered pattern of fibrocartilage la-
mellas with a collapse of the inner annulus morphologynchymal stem cell (ADSC) number in transplanted mice. (A) MRI
implant. Boxes refer to ADSC-implanted animals. *P <0.05,
als and represents the mean of all animals at different times after
rvertebral disc histological section of ADSC positivity to anti-HuNu and
μm. (C) Correlation between ADSC number and MRI intensity index
of one mm2 from a representative slide of disc slab. The point
Figure 5 Histological evaluation in placebo, transplanted and wild type (WT) mice. Representative histological sections of Safranin-O (A-F)
and Iba1 (G-I) immunostaining at the final follow-up period (12 weeks) from mice treated with placebo (A,B,G) or adipose mesenchymal stem
cells (C,D,H), and from WT mice (E,F,I). Safranin-O staining is shown at two different magnifications (A,C,E and B,D,F, respectively). Scale bar:
500 μm (A-F) and 100 μm (G-I). Iba1, ion calcium binding protein.
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ADSCs showed an improvement of the inner annulus
structure and a recovery of the disc structure, evident after
Safranin-O staining (Figure 5C,D), and appeared more
similar to the WT group (Figure 5E,F) than to the placebo
one. In addition, at high magnification, it was observed
that the tissue architecture was more structured in
ADSCs-treated mice than placebo ones, and again it was
similar to that of WT mice.
ADSCs, placebo and WT groups were also investigated
for the immunoinflammatory marker ion calcium binding
protein (Iba1), which is specifically expressed in macro-
phages and activated microglia. In placebo sections, we
observed an average of 45 to 50 positive cells per field
(Figure 5G). Conversely, reactive cells in the ADSC group
were by far less numerous (5 to 6 per field), and were
characterized by a low intensity staining (Figure 5H). The
number of positive cells in the ADSC group was found
similar to that of WT samples (Figure 5I).
Expression of HuNu, biglycan, aggrecan and Ki67 in mice
treated with ADSCs and placebo
We next analyzed HuNu (a marker for human cells) and
biglycan expression by immunohistochemistry. At 12 weeks
after transplantation, the staining with anti-HuNu in the
WT and placebo groups was found negative (Figure 6A,C),
whereas the ADSC-implanted mice showed positiveexpression (Figure 6B), indicating the presence of human
cells. Interestingly, further analyses revealed that Bgn−/0
mice treated with ADSCs were also biglycan-positive
(Figure 6E), as it occurs in the WT (Figure 6F). Al-
though the biglycan immunopositive signal was found
mainly localized intracellularly, this fluorescence was
also detectable in the extracellular region (Figure 6E, in-
sert), thus indicating that biglycan was also present in
the ECM. By contrast, cells in placebo-treated Bgn−/0
mice were biglycan negative (Figure 6D). It was interest-
ing to observe that biglycan-positive cells were also
HuNu-positive (Figure 6K), suggesting that, once trans-
planted, human ADSCs may produce biglycan in mice
lacking this capability. The analysis of HuNu expression
also revealed that some human cells were present also
in the adjacent disc (Figure 7A).
We then evaluated the total number of cells positive
for HuNu, biglycan and aggrecan in the whole discs. The
results showed that HuNu-positive cells were present in
all implanted discs from Bgn−/0 mice (Figure 7B, 1 to 5,
light gray), and this number correlated with the count in
a single histological slice (Figure 4C), indicating a diffuse
localization of ADSCs in the discs. In all transplanted
discs, biglycan- and aggrecan-positive cells were present,
and accounted for 35 to 40% and 15 to 35% of Hu-Nu-
positive cells, respectively (Figure 7B, 1 to 5, black and
dark gray bars). In all placebo discs, immunopositivity
Figure 6 Immunostaining of biglycan, 4',6-diamidino-2-phenylindole (DAPI) and human nuclei (HuNu) in the intervertebral disc (IVD).
Immunostaining of HuNu (A-C), biglycan (D-F), DAPI (G-I) and their colocalization (J-L) in IVDs are shown. The images are representative of
placebo (A,D,G,J) and adipose mesenchymal stem cell (ADSC) mice (B,E,H,K) at 12 weeks from injection, and of wild type (WT) (C,F,I,L) animals
at similar age. In the inserts of panel E and K, a magnification of biglycan immunostainings are shown. Scale bar, 50 μm.
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for aggrecan, a critical component of ECM of IVD [27],
was measurable at very low levels (Figure 7B, 6 to 10).
The number of aggrecan-positive cells in the placebo
group was found by far lower than that in the Bgn−/0
mice treated with ADSCs (Figures 7B and 8A,B).
In order to assess whether the ADSCs expressed aggre-
can spontaneously, we performed immunohistochemistry
on control cells and on cells growing in standard cultureFigure 7 Engraftment and co-localization of human nuclei (HuNu)-po
immunostaining of a disc adjacent to the injected one (vertebrae L1 to L2)
(ADSC)-implanted (lower panel) group are shown. Black arrows indicate the
HuNu- (light gray), biglycan- (black) and aggrecan- (dark grey) positive cells
are shown. Positive cells were measured in the whole discs of five individu
(6 to 10) at 12 weeks of treatment. Positive cells in five wild type (WT) animconditions, that is, in the absence of chondrogenic indu-
cing factors. In both cases, we found that immunopositivity
to aggrecan was undetectable in cultured ADSCs under
normal expansion conditions (data not shown), indicating
that they did not spontaneously express this large proteo-
glycan prior to implantation.
Finally, due to the significant presence of human ADSCs
in transplanted mice, in order to ascertain whether ADSCs
may undergo proliferation, we analyzed the expression ofsitive cells with biglycan. (A) Representative images of HuNu
in placebo (upper panel) and adipose mesenchymal stem cell
disc region were HuNu-positive cells are present. (B) The number of
in intervertebral discs from ADSC-transplanted and placebo groups
al animals transplanted with ADSCs (1 to 5), or injected with saline
als of similar age are shown on the right. Data are the mean ± S.D.
Figure 8 Immunolocalization of aggrecan and human nuclei
(HuNu) in placebo and adipose mesenchymal stem cell (ADSC)
groups. (A,B) Immuno-colocalization of aggrecan and 4',6-
diamidino-2-phenylindole (DAPI) in placebo (A) and ADSC-implanted
(B) groups. Scale bar, 200 μm. (C,D) Immunolocalization of Ki67, HuNu
and DAPI in placebo group (C) and ADSC-implanted (D) groups. Scale
bar, 50 μm.
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mice at 12 weeks after implant, co-localization of HuNu
and Ki67 staining was undetectable (Figure 8C,D).
Discussion
Different mouse models have been proposed to study the
physiological and pathophysiological behavior of degener-
ated IVD in spinal disorders. Numerous methods have
been developed, including mechanical instability, mechan-
ical compression, structural and chemical injury [28,29].
However, these models do not appear to entirely reflect
disc degeneration, but rather they mirror post-surgery disc
injury [30,31].
The Bgn−/0 mouse model exhibits many similarities to
the human IVD pathophysiology, and despite not en-
tirely reproducing it, it was reported to represent a valu-
able model for studying the time progression of IVD
degeneration as a chronic and linear degenerative process
in vivo [2]. Thus we considered the Bgn−/0 mouse as a
suitable tool for our preliminary in vivo evaluation of the
potential efficacy of ADSC implants as a therapeutic ap-
proach in progressive, degenerative disc disease.
In a previous study on Bgn−/0 mice, the degree of degen-
eration or deceleration of the disc degeneration process
was evaluated by histological/immunochemical approach
[2]. This type of evaluation of the IVD degeneration allows
the identification of alterations in cell proliferation and
ECM synthesis, but cannot provide information on the
progression or arrest of the disease over time. Instead,
changes in MRI signal intensity on T2-wi of IVDs, repre-
sents an important parameter for evaluating the degree of
disc degeneration [32]. Indeed, a decrease in signalintensity of T2-weighted MRI images correlates with the
IVD water content, which in turn is associated with reduc-
tion in nuclear proteoglycans, a main feature of disc de-
generation [33]. Thus, in the case of disc regeneration, the
high-signal intensity in the T2-wi is restored, reflecting
restoration of proteoglycan and water content [34]. It is
for these reasons that in the present investigation we
first followed the time progression of IVD degeneration
in Bgn−/0 mice by high resolution MRI, and then proc-
essed discs for histological analyses.
Our studies, performed by 7TMRI assessment and
histological evaluation, confirmed that IVD of Bgn−/0 mice
were in a more advanced degenerative state than those of
WT mice at every age examined, and thus, the biglycan
deficiency significantly accelerated disc degeneration. By
7TMRI assessment, we found that IVD degeneration was
particularly severe in Bgn−/0 mice at 16 months of age. For
this reason we started the cell therapy at this time.
Diverse therapeutic approaches have been proposed to
halt or reverse IVD degeneration [30]. These include
treatments with anabolic growth factors [35] and, more
recently, cell therapy using either intradiscal administra-
tion of NP-derived cells, or MSCs of different tissue ori-
gin [16,17,36]. In this context, the use of ADSCs was
recently proposed as a potential and effective therapeutic
tool for the treatment of IVD degeneration [37]. Prompted
by this evidence, we used human ADSCs isolated without
enzymatic digestion from abdominal adipose tissue speci-
mens. These cells in culture exhibit proliferative activity,
maintain typical mesenchymal markers, as well as differ-
entiation potential [18].
Some evidence of IVD regeneration in an autologous
ADSC-injected rabbit model has been previously provided
[38]. The present study shows for the first time that ADSC
transplantation is beneficial in ameliorating degeneration
in a chronic model of IVD, as demonstrated by MRI, histo-
logical and immunofluorescence findings.
In particular, the ameliorative effect of ADSCs on IVD
degeneration was evident as MRI index values at all
investigated times, with significant differences when com-
pared to the pre-operative value. Of relevance, the MRI
index values of the ADSC-treated group were significantly
higher than those of the placebo group at all investigated
times. Moreover, we found that the MRI intensity index
correlated with the number of cells found in the im-
planted discs, supportive of an increment in water content
and proteoglycans synthesis in the presence of ADSCs.
The histological assessment by Safranin-O staining con-
firmed that ADSC implants improved the structure of
IVD in Bgn−/0 mice. Indeed, we observed a recovery of
disc structure, supporting that neosynthesis of ECM com-
ponents occurred in transplanted discs. However, it is im-
portant to note that transplanted cells may also have
transient paracrine effects, and their survival in the site of
Marfia et al. Arthritis Research & Therapy 2014, 16:457 Page 11 of 13
http://arthritis-research.com/content/16/6/457injection could not be the only one relevant aspect in-
volved in disc regeneration [37].
Although the beneficial effects of ADSC transplant-
ation were already significant after 3 weeks, these effects
appeared not to progress, but rather to be maintained
along with time. Notwithstanding the ameliorative ef-
fects of ADSC transplantation on disc degeneration, the
apparent lack of increased beneficial effects over longer
periods of time may indicate that a unique treatment
could not be sufficient for optimal therapy, and that dif-
ferent treatments (in terms of schedules and/or trans-
planted cell number) could be more effective than the
one used for longer periods. Further experiments are
needed to clarify if serial transplants, and/or a higher
number of implanted cells, as well as ADSC injections at
earlier degeneration times could be effective in amelior-
ating the recovery process of IVD degeneration.
Immunofluorescence analyses performed with anti-
bodies against human HuNu, Ki67, biglycan, and aggrecan
provided additional important results, which we subse-
quently discuss here. Of critical importance, our data re-
vealed the presence of HuNu positive cells, that is, of
human cells, in transplanted IVDs all over time, and up to
12 weeks post-transplant. Thus, it emerges that, after im-
plantation into the degenerated IVDs of biglycan-deficient
mice, some human ADSCs can survive for at least
12 weeks in the peculiar microenvironment of the IVD,
where hypoxia, low nutrition, acidic pH, mechanical load-
ing, endogenous proteinases, and cytokines [39] would
not favor exogenous ADSC survival. We also observed
some positivity for anti-HuNu also in the adjacent discs,
possibly due to the leakage of cells during injection.
However, notwithstanding the presence of ADSCs in
IVDs, at 12 weeks we were unable to find any evidence
of cell division, as the proliferation marker Ki67 was un-
detectable at this time. However, taking into account
that 12 weeks is a prolonged time after transplantation,
we cannot exclude that ADSC proliferation may occur at
earlier times. As indirect support of this hypothesis,
histological images revealed that the implanted cells are
present as tight clusters of cells, which often indicates a
sign of cell division. Thus, ADSCs might have undergone
cell division in the early weeks and then stopped in the
later weeks.
Additional important evidence provided by our study
is that a relevant percentage of ADSCs transplanted on
IVD of Bgn−/0 mice showed positivity to anti-human
biglycan, and also to aggrecan, supporting the concept
that a differentiation process in ADSCs has occurred at
12 weeks from transplant. This is in agreement with pre-
vious studies on cultured cells, demonstrating the stem
cell population within the adipose stromal compartment
in human processed lipoaspirate can differentiate toward
the osteogenic, adipogenic, myogenic, and chondrogeniclineages, and that they express biglycan and aggrecan in
chondrogenic differentiation conditions [40]. Notably, al-
though human mesenchymal stem cells have been re-
ported to spontaneously express some ECM proteins such
as cartilage oligomeric matrix protein [41], we obtained
evidence that ADSCs did not spontaneously express
aggrecan when cultured in the absence of chondrogenic
inducing factors, that is, in the normal expansion condi-
tions we used prior to implantation. Therefore, it emerges
that human ADSCs are multipotential stem cells capable
of undergoing chondrogenic differentiation in vivo, and it
is suggested that the diseased disc environment is able to
induce the expression of both biglycan and the cartilage
specific proteoglycan aggrecan. Whereas both proteins ap-
pear to be de novo produced by implanted ADSCs, as
placebo-treated mice showed some positivity to anti-
human aggrecan antibody, we cannot exclude that ADSCs
treatment may stimulate an endogenous production of
aggrecan too, by a paracrine effect of the cells in the disc.
Overall, it is tempting to speculate that, once implanted
into IVDs, ADSCs initially may undergo cell division and
forms tight clusters, and subsequently, stimulated by the
local microenvironment, close-fitting clusters of ADSCs
undergo chondrogenic differentiation. In agreement, cell
density was reported to be crucial for chondrogenic differ-
entiation, pellet mass cultures being essential for the
chondrogenic differentiation of MSCs [42].
Two further important findings of our study deserve
comments. First, it is worth noting that the ameliorative
effect of ADSC implant on disc degeneration was ob-
served in old animals and these had severe disc damage.
This underlies the potential of ADSC implant as effect-
ive in our in vivo mouse model. Second, during the
study period, we did not observe any host-graft rejection,
further supporting the effectiveness of ADSC implants
in IVDs. In this context, the survival of IVD-implanted
ADSCs may be favored by the fact that the IVD represents
a privileged implantation site from the immunological
point of view, mesenchymal stem cells derived from differ-
ent adult tissues showing advantages from these immuno-
suppressive effects [43-45].
Conclusion
In conclusion, our study shows for the first time that the
ADSC treatment can be beneficial in vivo in a mouse
model of spontaneous IVD degeneration. ADSCs exert
their effects at various levels, overall positively influencing
the degeneration process and finally exhibiting long-term
engraftment and tissue recovery. ADSCs appear effective
in IVD degeneration by providing exogenous biglycan,
and simultaneously stimulating the endogenous produc-
tion of aggrecan, both these proteoglycans being crucial in
re-establishing the IVD matrix composition closer to the
normal one [46].
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ary in vivo evidence that ADSC transplants may represent
an effective treatment for degenerative disc disease in
humans. Although the Bgn−/0 mouse is a valuable model
for investigating disc degeneration [2], it is worth noting
that this model does not entirely reproduce the human
disc pathophysiology. Future investigations in different
models such as non-human primate models are prompted
by this research, and will hopefully confirm the validity of
the proposed therapy.
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